A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p
GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s
Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t
Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year
Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e